<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95933">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02120456</url>
  </required_header>
  <id_info>
    <org_study_id>LP0084-1015</org_study_id>
    <nct_id>NCT02120456</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis</brief_title>
  <official_title>Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1:  To identify Maximum Tolerated Dose (MTD) levels of LEO 43204 after once daily
      treatment for two consecutive days

      Part 2:  To evaluate the efficacy of LEO 43204 in two doses after once daily treatment for
      two consecutive days compared to vehicle
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Part 1:  Dose Limiting Toxicity up to and including Day 8</measure>
    <time_frame>8 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2:  Percent Reduction in AK Count</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent reduction in AK count from baseline to Week 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2:  Complete Clearance of AKs</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:  Partial Clearance of AKs</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Partial clearance of AKs at Week 8, defined as at least 75% reduction from baseline in AK count</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">227</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>LEO 43204</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, dose-escalation, 2-day treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 43204 Dose X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 43204 dose X once daily for two consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 43204 Dose Y</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 43204 dose Y once daily for two days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for two days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 43204</intervention_name>
    <arm_group_label>LEO 43204</arm_group_label>
    <arm_group_label>LEO 43204 Dose X</arm_group_label>
    <arm_group_label>LEO 43204 Dose Y</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the arm

          -  Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the
             extremities or trunk

        Exclusion Criteria:

          -  Location of the treatment area

               -  within 5 cm of an incompletely healed wound

               -  within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma
                  (SCC)

          -  Prior treatment with ingenol mebutate gel on the treatment area

          -  Lesions in the treatment areas that have:

               -  atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous
                  horns) and/or

               -  recalcitrant disease (e.g., did not respond to cryotherapy on two previous
                  occasions)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Goldenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medicine, Dermatology Faculty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aruna Sharma</last_name>
    <phone>905-747-2354</phone>
    <email>aruna.sharma@leo-pharma.com</email>
  </overall_contact>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>April 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
